VIGIL NEUROSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.03 USD | +2.03% |
|
+0.75% | +19.23% |
| Jul. 01 | Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 3000E Value Index | CI |
| Jul. 01 | Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Value Index | CI |
Presenter SpeechDavid Gray (Executives)All right. Thank you very much. It's my pleasure to be ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimerâs disease in genetically defined subpopulations.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.03
USD
Average target price
16.88
USD
Spread / Average Target
+318.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.23% | 148M | |
| +18.97% | 44.44B | |
| +41.98% | 40.03B | |
| -10.06% | 37.68B | |
| +31.15% | 31.46B | |
| -7.79% | 27.29B | |
| +13.32% | 26.29B | |
| +43.05% | 13.8B | |
| +31.28% | 12.46B | |
| -7.41% | 11.26B |
- Stock Market
- Equities
- VIGL Stock
- News Vigil Neuroscience, Inc.
- Transcript : Vigil Neuroscience, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10
